SCHEMBL23015752

SCHEMBL23015752

Cc1ccnc(NC(=O)c2cccnc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.67
NPC1 O15118 4/20 0.67
TDP1 Q9NUW8 1/20 0.63
MAPK8 P45983 1/20 0.62
MAPK10 P53779 1/20 0.62
ATM Q13315 1/20 0.61
KMT2A Q03164 3/20 0.60
IDE P14735 1/20 0.59
ALDH1A1 P00352 1/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
PKM P14618 3/20 0.56
HSD17B10 Q99714 1/20 0.56
LMNA P02545 1/20 0.55
HIF1A Q16665 1/20 0.55
PRKAB2 O43741 1/20 0.54
PRKAG1 P54619 1/20 0.54
PRKAA2 P54646 1/20 0.54
PRKAA1 Q13131 1/20 0.54
PRKAG3 Q9UGI9 1/20 0.54
PRKAG2 Q9UGJ0 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14082544 0.85 RAB9A (0.63) RAB9ANPC1TDP1ATMKMT2A
SCHEMBL17065565 0.85 NPC1 (0.89) RAB9ANPC1ATMKMT2AALDH1A1
SCHEMBL2176413 0.85 NPC1 (0.89) RAB9ANPC1ATMKMT2AALDH1A1
SCHEMBL8555112 0.84 NPC1 (0.72) RAB9ANPC1ATMKMT2AIDE
SCHEMBL23446461 0.83 MAPK8 (0.62) RAB9ANPC1TDP1MAPK8MAPK10
SCHEMBL23410523 0.83 MAPK8 (0.62) RAB9ANPC1TDP1MAPK8MAPK10
SCHEMBL29899004 0.83 MAPK8 (0.62) RAB9ANPC1TDP1MAPK8MAPK10
SCHEMBL23015751 0.82 NPC1 (0.64) RAB9ANPC1TDP1MAPK8MAPK10
SCHEMBL20068995 0.82 TDP1 (0.62) RAB9ANPC1TDP1KMT2AIDE
SCHEMBL23015836 0.82 TDP1 (0.58) RAB9ANPC1TDP1MAPK8MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271953-A1 Novel compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2023-08-31 US disclosed
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors PHARMASUM THERAPEUTICS AS (NO) 2021-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors DYRK1A, DYRK1B, PDK2 RAB9A 1200/4885NPC1 2121/4885TDP1 780/4885
US-20230271953-A1 Novel compounds for treatment of diseases related to DUX4 expression UTRN, ZFX, CBX6 RAB9A 1291/4885NPC1 3212/4885TDP1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.